Vasoactive intestinal polypeptide and substance P in the pathogenesis of atopic dermatitis
Neurogenic components are probably involved in the pathogenesis of atopic dermatitis (AD) and several neuropeptides have been implicated in the mechanisms underlying this disease. The aim of the present study was to evaluate by radio-immunoassay (RIA), the vasoactive intestinal polypeptide (VIP) and substance P (SP) content in whole-skin homogenates of AD lesions. RIA was performed using an antiserum, AH78, recognizing the carboxy-terminal fragment VIP (22-28) and a polyclonal antiserum directed against SP. VIP levels were markedly increased in lesional AD skin (5.62 +/- 1.25 pmol/g tissue) vis-à-vis controls (0.43 +/- 0.08 pmol/g tissue), whereas SP levels were significantly lower in lesional skin (0.25 +/- 0.03 pmol/g tissue) than in normal skin (0.97 +/- 0.24 pmol/g tissue). The results confirm that VIP and SP are relevant to the pathogenesis of AD and their imbalance might reflect diverse roles of these NP in the modulation of AD lesion.
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
1992 |
---|---|
Erschienen: |
1992 |
Enthalten in: |
Zur Gesamtaufnahme - volume:176 |
---|---|
Enthalten in: |
Acta dermato-venereologica. Supplementum - 176(1992) vom: 15., Seite 90-2 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Giannetti, A [VerfasserIn] |
---|
Themen: |
33507-63-0 |
---|
Anmerkungen: |
Date Completed 03.02.1993 Date Revised 13.01.2021 published: Print Citation Status MEDLINE |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
NLM01262649X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM01262649X | ||
003 | DE-627 | ||
005 | 20231221053121.0 | ||
007 | tu | ||
008 | 231221s1992 xx ||||| 00| ||eng c | ||
028 | 5 | 2 | |a pubmed24n0042.xml |
035 | |a (DE-627)NLM01262649X | ||
035 | |a (NLM)1282289 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Giannetti, A |e verfasserin |4 aut | |
245 | 1 | 0 | |a Vasoactive intestinal polypeptide and substance P in the pathogenesis of atopic dermatitis |
264 | 1 | |c 1992 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a Date Completed 03.02.1993 | ||
500 | |a Date Revised 13.01.2021 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Neurogenic components are probably involved in the pathogenesis of atopic dermatitis (AD) and several neuropeptides have been implicated in the mechanisms underlying this disease. The aim of the present study was to evaluate by radio-immunoassay (RIA), the vasoactive intestinal polypeptide (VIP) and substance P (SP) content in whole-skin homogenates of AD lesions. RIA was performed using an antiserum, AH78, recognizing the carboxy-terminal fragment VIP (22-28) and a polyclonal antiserum directed against SP. VIP levels were markedly increased in lesional AD skin (5.62 +/- 1.25 pmol/g tissue) vis-à-vis controls (0.43 +/- 0.08 pmol/g tissue), whereas SP levels were significantly lower in lesional skin (0.25 +/- 0.03 pmol/g tissue) than in normal skin (0.97 +/- 0.24 pmol/g tissue). The results confirm that VIP and SP are relevant to the pathogenesis of AD and their imbalance might reflect diverse roles of these NP in the modulation of AD lesion | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a Peptide Fragments |2 NLM | |
650 | 7 | |a Substance P |2 NLM | |
650 | 7 | |a 33507-63-0 |2 NLM | |
650 | 7 | |a Vasoactive Intestinal Peptide |2 NLM | |
650 | 7 | |a 37221-79-7 |2 NLM | |
650 | 7 | |a vasoactive intestinal peptide (22-28) |2 NLM | |
650 | 7 | |a 47900-24-3 |2 NLM | |
700 | 1 | |a Fantini, F |e verfasserin |4 aut | |
700 | 1 | |a Cimitan, A |e verfasserin |4 aut | |
700 | 1 | |a Pincelli, C |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Acta dermato-venereologica. Supplementum |d 1950 |g 176(1992) vom: 15., Seite 90-2 |w (DE-627)NLM000449644 |x 0365-8341 |7 nnns |
773 | 1 | 8 | |g volume:176 |g year:1992 |g day:15 |g pages:90-2 |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 176 |j 1992 |b 15 |h 90-2 |